厄贝沙坦联合美托洛尔治疗慢性充血性心力衰竭分析

Irbesartan Combined With Metoprolol in the Treatment of Chronic Congestive Heart Failure

目的观察分析厄贝沙坦联合美托洛尔治疗慢性充血性心力衰竭(心衰)患者的临床治疗效果。方法选择我院2015年9月—2017年12月收治的88例慢性充血性心衰患者作为本次的研究对象,随机分为联合组和对照组,每组44例。对照组患者应用厄贝沙坦进行治疗,联合组患者应用厄贝沙坦联合美托洛尔进行治疗。比较两组患者的临床疗效。结果联合组患者的临床总有效率高于对照组(95.45%vs.79.55%),差异具有统计学意义(P <0.05)。两组患者经过治疗后,LVEDd、LVESd以及Nt-pro-BNP均低于治疗前,差异具有统计学意义(P <0.05);联合组患者治疗后LVEDd、LVESd以及Nt-pro-BNP较对照组患者降低更加显著,差异具有统计学意义(P <0.05)。结论厄贝沙坦联合美托洛尔治疗慢性充血性心衰患者可以取得显著的临床治疗效果,有效的改善患者的生命体征以及心功能。

Objective To observe and analyze the clinical efficacy of irbesartan combined with metoprolol in the treatment of patients with chronic congestive heart failure.Methods 88 patients with chronic congestive heart failure treated in our hospital from September 2015 to December 2017 were selected as the research subjects and were randomly divided into the combined group and the control group,with 44 cases in each group.The patients in the control group were treated with irbesartan,and the patients in the combined group were treated with irbesartan combined with metoprolol.The clinical effects of the two groups were compared.Results The total effective rate of the combined group was significantly higher than that of the control group(95.45%vs.79.55%),and the difference was statistically significant(P<0.05).After treatment,LVEDd,LVESd and Nt-pro-BNP in the two groups were lower than those before treatment,and the difference was statistically significant(P<0.05).After treatment,the levels of LVEDd,LVESd and Nt-pro-BNP in the combined group were significantly lower than those in the control group(P<0.05).Conclusion Irbesartan combined with metoprolol can achieve significant clinical therapeutic effect in the treatment of chronic congestive heart failure,effectively improving the patient's vital signs and cardiac function.